Key result
New oral anticoagulants, including direct thrombin and Xa inhibitors, offer promising alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation despite potential limitations.
Why the study?
Do new oral anticoagulants prevent stroke compared to vitamin K antagonists in patients with atrial fibrillation?
Population
Patients with atrial fibrillation (AF) requiring lifelong oral anticoagulation for stroke prevention
Comparison
New oral anticoagulants vs Vitamin K antagonists (VKAs) / warfarin
Design
Review
Authors
Loading...
May support individualized anticoagulant selection in atrial fibrillation; leaves open definitive comparisons versus optimized vitamin K antagonists.
Do new oral anticoagulants prevent stroke compared to vitamin K antagonists in patients with atrial fibrillation?
This review highlights that while new oral anticoagulants offer alternatives to warfarin for stroke prevention in atrial fibrillation, the perceived drawbacks of warfarin may sometimes be clinical assets, requiring individualized patient management.
Jack Ansell (2010) conducted a review in Atrial fibrillation. New oral anticoagulants (direct thrombin and Xa inhibitors) vs. Vitamin K antagonists (Warfarin) was evaluated. New oral anticoagulants, including direct thrombin and Xa inhibitors, offer promising alternatives to vitamin K antagonists for stroke prevention in atrial fibrillation despite potential limitations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: